Skip Navigation

Neuro-Oncology 2004 6(1):38-43; doi:10.1215/S1152851703000188
© 2004 by Society
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chua, S. L.
Right arrow Articles by Cher, L. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chua, S. L.
Right arrow Articles by Cher, L. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 by the Society forNeuro-Oncology

Phase 2 study of temozolomide and Caelyx in patients with recurrentglioblastoma multiforme

Susan L. Chua, Mark A. Rosenthal1, Shirley S. Wong, David M. Ashley, Anne-marie Woods, Anthony Dowling and Lawrence M. Cher

Centre for Developmental Cancer Therapeutics,Parkville, Victoria, affiliates: Department of Clinical Haematology andMedical Oncology, Royal Melbourne Hospital, Parkville, Victoria 3050 (S.L.C.,M.A.R., S.S.W., A.W.); Department of Medical Oncology,Royal Children's Hospital, Parkville, Victoria 3050 (D.M.A.); Department of Medical Oncology, St. Vincent's Hospital,Fitzroy, Victoria 3065 (A.D.); and Department ofMedical Oncology, Austin and Repatriation Medical Centre, Heidelberg, Victoria3184 (L.M.C.); Australia

1 Address correspondence to Mark Rosenthal, Department of Clinical Haematologyand Medical Oncology, Royal Melbourne Hospital, Parkville, Victoria 3050,Australia(mark.rosenthal{at}mh.org.au).


  Abstract

Temozolomide has established activity in the treatment of recurrentglioblastoma multiforme (GBM). Caelyx (liposomal doxorubicin) has establishedactivity in a broad range of tumors but has not been extensively evaluated inthe treatment of GBM. Phase 1 data suggest that temozolomide and Caelyx can becombined safely at full dose. In this phase 2 study, combination temozolomide(200 mg/m2 orally, days 1-5) and Caelyx (40 mg/m2 i.v.,day 1) was given every 4 weeks to a cohort of 22 patients with recurrent GBM,who received a total of 109 cycles (median 3.5 cycles). The median age of thepatients was 55 years (range, 31-80 years), and 17 were male. All patients hadreceived radiotherapy, but only 2 had received prior chemotherapy. One patient(5%) had a complete response, 3 patients (14%) had a partial response, and 11patients (50%) had stable disease. The median time to progression for thecohort was 3.2 months (range, 1-13 months). Median overall survival was 8.2months (range, 1-16+ months). Seven patients (32%) were progression free at 6months. Hematological toxicity included grade 3/4 neutropenia in 4 patients(18%) and grade 3/4 thrombocytopenia in 4 patients (18%). Grade 3nonhematologic toxicity included rash in 3 patients (14%), nausea and vomitingin 1 patient (4%), hypersensitivity reaction to Caelyx in 3 patients (14%),and palmar-plantar toxicity in 1 patient (4%). We conclude that thecombination of temozolomide and Caelyx is well tolerated, results in a modestobjective response rate, but has encouraging disease stabilization in thetreatment of recurrent GBM.

Received April 30, 2003; Accepted September 22, 2003


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.